User profiles for Uğur Şahin
 | Ugur SahinProfessor of Immunology Verified email at uni-mainz.de Cited by 68314 |
[HTML][HTML] Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
…, S Mather, PR Dormitzer, U Şahin… - New England journal …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …
[HTML][HTML] SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3
Immune Response to a Third Dose of BNT162b2 A third dose of the BNT162b2 vaccine was
administered to 23 volunteers 8 to 9 months after the second dose, and the immune …
administered to 23 volunteers 8 to 9 months after the second dose, and the immune …
[HTML][HTML] Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
…, AR Falsey, PR Dormitzer, WC Gruber, U Şahin… - Nature, 2020 - nature.com
In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19),
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
Neutralization of SARS-CoV-2 lineage B. 1.1. 7 pseudovirus by BNT162b2 vaccine–elicited human sera
Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage
called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more …
called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more …
RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study
…, KE Lyke, V Raabe, PR Dormitzer, KU Jansen, U Şahin… - Medrxiv, 2020 - medrxiv.org
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections
and the resulting disease, coronavirus disease 2019 (COVID-19), have spread to millions of …
and the resulting disease, coronavirus disease 2019 (COVID-19), have spread to millions of …
Determination of fluoride in various samples and some infusions using a fluoride selective electrode
…, Ş KARTAL, U ŞAHİN - Turkish Journal of …, 2004 - journals.tubitak.gov.tr
The determination of fluoride in some environmental samples was performed using a fluoride
ion-selective electrode. Fluoride concentrations were determined in drinking waters (from …
ion-selective electrode. Fluoride concentrations were determined in drinking waters (from …
[HTML][HTML] Bivalent Omicron BA. 1–Adapted BNT162b2 booster in adults older than 55 years
Background The emergence of immune-escape variants of severe acute respiratory
syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide protection …
syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide protection …
[HTML][HTML] Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
…, PR Dormitzer, KU Jansen, U Şahin… - … England Journal of …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
[HTML][HTML] Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
…, S Mather, PR Dormitzer, U Şahin… - … England Journal of …, 2021 - Mass Medical Soc
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome …
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome …
[HTML][HTML] Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age
Background Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently
needed in children younger than 12 years of age. Methods A phase 1, dose-finding study …
needed in children younger than 12 years of age. Methods A phase 1, dose-finding study …